Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.37 |
| ▸ | LIPE | Q05469 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22040325 | 1.00 | ROCK2 (0.41) | ROCK2PDE10ALIPELRRK2ALOX5AP | |
| SCHEMBL31441507 | 0.94 | ROCK2 (0.40) | ROCK2PDE10ALIPELRRK2ALOX5AP | |
| SCHEMBL31441748 | 0.94 | ROCK2 (0.40) | ROCK2PDE10ALRRK2ALOX5APFEN1 | |
| SCHEMBL25429896 | 0.93 | ROCK2 (0.40) | ROCK2PDE10ALRRK2ALOX5APFEN1 | |
| SCHEMBL31441478 | 0.92 | LRRK2 (0.43) | ROCK2PDE10ALRRK2ALOX5APFEN1 | |
| SCHEMBL31441548 | 0.87 | LRRK2 (0.45) | ROCK2PDE10ALRRK2 | |
| SCHEMBL31441643 | 0.81 | ROCK2 (0.42) | ROCK2 | |
| SCHEMBL365301 | 0.81 | L3MBTL1 (0.36) | LIPE | |
| SCHEMBL29900384 | 0.81 | L3MBTL1 (0.36) | LIPE | |
| SCHEMBL12098073 | 0.81 | ALOX5AP (0.35) | ROCK2LIPEALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024208292-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITOR, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2024-10-10 | — | — | WO | disclosed |
| CN-111465410-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-111526890-B | Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine | H.隆德贝克有限公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | ROCK2 2754/4885PDE10A 2582/4885LIPE 2776/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | ROCK2 3262/4885PDE10A 2380/4885LIPE 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.